December 13, 2002
MEDIA CONTACT: Trent Stockton
PHONE: 410-955-8665

Death From Liver Disease Major Threat to Men with Hepatitis B and HIV 

Men infected with a combination of hepatitis B virus and HIV are 17 times more likely to die from liver disease than men infected with hepatitis B alone, according to a study by researchers at Johns Hopkins published in the Dec. 14, 2002, issue of The Lancet.

"These results underscore the importance of prevention, treatment and comprehensive management of hepatitis B in people infected with HIV," says Chloe Thio, M.D., assistant professor of medicine in the Division of Infectious Diseases at Johns Hopkins and lead author of the study.

The low rate of liver disease-related deaths in those with hepatitis B alone is consistent with the 20 to 30 years typically needed for complications from hepatitis B to develop, explains Thio. However, because HIV and hepatitis B are transmitted in the same way, coinfection is common and up to 10 percent of HIV-infected individuals also have ongoing hepatitis B infection, says Thio.

"Our results suggest that HIV increases the severity of hepatitis B infections, and that physicians may see an increase of hepatitis B-related liver disease in the 1 million people living with HIV in the United States," says Thio.

Thio and colleagues analyzed clinical data and blood and tissue samples collected from 1994 to 2000 from 5,293 men who participated in the Multicenter AIDS Cohort Study. The researchers compared death rates from liver disease in four patient groups: HIV-infected individuals, hepatitis B-infected individuals, individuals infected with both viruses, and virus-free individuals. They found that 326 men (6 percent) had hepatitis B, of whom 213 (65 percent) also had HIV. Of the 4,987 men without hepatitis B, 2,346 (47 percent) were infected with HIV. Liver disease-related death was highest among those with advanced HIV disease, as measured by CD4 cell count, and was twice as high after 1996, when highly effective HIV therapies were introduced.

"Determining possible adverse effects of long-term use of HIV therapies and assessing the possible interaction with hepatitis infections are central questions that our ongoing studies will address," says Alvaro Muñoz, Ph.D., professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health.

According to the World Health Organization, hepatitis B is the leading cause of chronic liver disease and liver cancer, and is the ninth leading cause of death worldwide.

Other authors of the study are David L. Thomas, M.D., and Richard Skolasky Jr., M.A., of the Johns Hopkins School of Medicine, Eric Seaberg, Ph.D, of the Johns Hopkins Bloomberg School of Public Health, John Phair, M.D., of Northwestern University and Barbara Visscher, Dr.P.H. of the UCLA School of Public Health. The study was funded by the National Institutes of Allergy and Infectious Diseases.

Related Web sites:
Johns Hopkins Division of Infectious Diseases:
Johns Hopkins Bloomberg School of Public Health:


-- JHMI --
Search Press Releases

News Media Home | Hopkins Medicine Home